| Literature DB >> 30783127 |
Xiujuan Meng1, Jun Yang2, Juping Duan1, Sidi Liu1, Xun Huang1, Ximao Wen1, Xin Huang1, Chenchao Fu1, Jie Li1, Qingya Dou1, Yao Liu1, Jia Wang2, Qun Yan3, Mingxiang Zou3, Wenen Liu3, Zhong Peng4, Liang Chen5, Chunhui Li6, Anhua Wu7.
Abstract
Carbapenem-resistant K. pneumoniae (CR-KP) posts significant public health challenge worldwide. The aim of this study is to assess clinical characteristics and molecular epidemiology of CR-KP infections with Multilocus sequence typing (MLST) and Matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF) in Central China. A total of 71 CR-KP isolates were recovered in a teaching hospital from October 2014 to December 2015. Among all CR-KP isolates, 73.2% (52) produced K. pneumoniae carbapenemases-2 (KPC-2). Eighteen ST types were identified by MLST, among these ST types, forty-seven isolates belonged to ST11 type, which was the predominant outbreak strain in China, and most ST11 isolates produced KPC-2. Eleven mass spectrometry (MS) types were identified by MALDI-TOF MS analysis, 53.5% isolates were MS4 and MS6, which matched with ST11 in MLST analysis. CR-KP infection was associated with increased medical cost and longer hospitalization. Therefore, we found that KPC-2-producing ST11 (MS4 and MS6) CR-KP isolates were the predominant clone identified by MLST and MALDI-TOF, and CR-KP infection was associated with increased hospital costs and longer hospitalization.Entities:
Year: 2019 PMID: 30783127 PMCID: PMC6381170 DOI: 10.1038/s41598-018-38295-8
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1The distribution of carbapenem-resistant K. pneumoniae. The percentage of carbapenem-resistant K. pneumoniae (CR-KP) strains recovered from different wards and different sites are presented in this figure. Categorical variables in the figure are (no., %), ICU = intensive care unit.
The antibiotic-resistance of the two groups {carbapenem-resistant KP (CR-KP) and carbapenem-susceptible KP}.
| CR-KP(n = 71) | CS-KP(n = 71) | OR(95%CI) |
| |
|---|---|---|---|---|
| ESBL | 5/71 (7%) | 33/71 (46%) | 28.17 (0.03–0.24) | >0.001 |
| Piperacillin/sazobactam | 66/69 (96%) | 4/71 (6%) | 113.42 (79.39–1710.42) | >0.001 |
| Ampicillin/sulbactam | 63/64 (98%) | 29/64 (45%) | 44.68 (9.93–582.33) | >0.001 |
| Cefoperazone/sulbactam | 63/69 (91%) | 3/71 (4%) | 106.49 (57.09–992.20) | >0.001 |
| Amoxillin/clavulanic acid | 6/6 (100%) | 5/7 (71%) | 2.03 (0.88–2.24) | 0.16 |
| Cefazolin | 67/69 (97%) | 40/70 (57%) | 31.31 (5.69–110.81) | >0.001 |
| Ceftazidime | 62/64 (97%) | 16/65 (25%) | 70.44 (20.83–432.76) | >0.001 |
| Ceftriaxone | 69/71 (97%) | 35/71 (49%) | 41.54 (8.07–156.02) | >0.001 |
| Cefoxitin | 6/6 (100%) | 3/7 (43%) | 4.95 (0.99–5.49) | 0.03 |
| Cefepime | 67/71 (94%) | 14/71 (20%) | 80.73 (21.25–218.84) | >0.001 |
| Cefotetan | 60/65 (92%) | 1/67 (1.5%) | 109.47 (89.95–6973.50) | >0.001 |
| Aztreonam | 65/69 (94%) | 24/71 (34%) | 55.13 (10.35–97.83) | >0.001 |
| Tobramycin | 57/69 (83%) | 16/71 (23%) | 50.61 (7.08–37.64) | >0.001 |
| Amikacin | 45/70 (64%) | 0/71 (0%) | 67.04 (−) | >0.001 |
| Gentamycin | 56/70 (80%) | 13/71 (18%) | 53.68 (7.71–41.32) | >0.001 |
| Ciprofloxacin | 53/70 (76%) | 14/71 (20%) | 44.32 (5.70–28.25) | >0.001 |
| Levofloxacin | 50/70 (72%) | 10/71 (14%) | 47.42 (6.54–35.54) | >0.001 |
| Trimethoprim-sulfamethoxazole | 17/71 (24%) | 25/71 (35%) | 2.16 (0.28–1.20) | 0.14 |
| Nitrofurantoin | 68/69 (98%) | 65/71 (92%) | 3.61 (0.74–53.57) | 0.06 |
NOTE. Categorical variables are no/total no. (%), CR-KP is carbapenem-resistant K. pneumoniae, CS-KP is carbapenem-susceptible K. pneumoniae,. OR is Odds Ratio, 95%CI is Confidence Interval.
Figure 2Representative spectra of the carbapenem-resistant K. pneumoniae strains. A and B show spectra of two representative strains (the strains marked 1 and 2) in our study, respectively.
Figure 3Magnified dendrogram (representation of hierarchical cluster analysis) of the carbapenem-resistant K. pneumoniae. ST types, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry types, resistant genes, and infection wards of the carbapenem-resistant K. pneumoniae strains are described.
Figure 4Monthly distribution of multilocus sequence typing (ST) and mass spectrometry types (MS). A shows the distribution of ST types of multilocus sequence typing, ST11cluster and a peak period for outbreak in May and June 2015. B shows the distribution of mass spectrometry (MS) types, mainly MS6, MS4, and MS8 clusters.
The mortality and medical costs of carbapenem-resistant KP(CR-KP) and carbapenem-susceptible KP (CS-KP) groups.
| CR-KP (n = 71) | CS-KP (n = 71) |
|
| |
|---|---|---|---|---|
| Mortality (%) | 28/71 (39.4%) | 16/71 (25.7%) | 4.74 | 0.03 |
| Total costs (¥) | 162618 (9098–1078466) | 104225 (18145–529492) | −2.87 | >0.001 |
| Medical examination | 6822 (174–29670) | 5077 (284–28496) | −1.09 | 0.27 |
| Medical test costs (¥) | 14124 (1894–74174) | 8434 (846–46706) | −2.93 | >0.001 |
| Total drug costs (¥) | 78579 (965–442989) | 38651.5 (8300–222058) | −2.96 | >0.001 |
| Anti-infective drug costs (¥) | 19755 (63–243121) | 7171 (0–63506) | −3.64 | >0.001 |
| Total hospital stay days | 37 (4–227) | 28 (7–149) | −2.33 | 0.02 |
NOTE. Continuous variables are median(min-max), CR-KP is carbapenem-resistant K. pneumoniae, CS-KP is carbapenem-susceptible K. pneumoniae.